ArticleBlood cell therapy2025
G-CSF-combined conditioning in allogeneic transplantation for non-remission acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2).
Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a dismal prognosis and poor response to conventional chemotherapy. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for adult AML with inv(3)/t(3;3) during complete remission (CR). Nevertheless, because fewer than half of patients achieve a CR with induction conventional chemotherapy, allogeneic HCT is frequently performed for AML with inv(3)/t(3;3) in non-remission. Here, we report six patients with adult AML with inv(3)/t(3;3) in non-remission who underwent allogeneic HCT at our institute between 2010 and 2024. The median age at the time of HCT was 43.5 years (range, 28-53 years). The median proportion of blasts in the bone marrow at HCT was 47.5% (range, 0.7-75.0%). The median duration from diagnosis to HCT was 65.5 days (range, 41-123 days). A total of five patients received single-unit cord blood transplantation, and one received bone marrow transplantation from an HLA-matched sibling donor. All patients received a myeloablative conditioning regimen, including 12 Gy total body irradiation and granulocyte colony-stimulating factor (G-CSF) combined with high-dose cytarabine, as well as standard cyclosporine and methotrexate for graft-versus-host disease prophylaxis. With a median follow-up of 41 months for survivors, three patients experienced relapse at 18, 5, and 2 months, whereas the remaining three patients were alive and disease-free at 173, 110, and 30 months after HCT. Our data demonstrate that G-CSF-combined myeloablative conditioning following allogeneic HCT could lead to favorable long-term remission for adult AML with inv(3)/t(3;3) in non-remission at HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.